EGFR、HER2在结直肠癌患者血清与组织中的表达及其临床意义分析

宋均飞; 刘弋

doi:10.16462/j.cnki.zhjbkz.2016.04.020

EGFR、HER2在结直肠癌患者血清与组织中的表达及其临床意义分析

doi: 10.16462/j.cnki.zhjbkz.2016.04.020

宋均飞,
刘弋^,

安徽医科大学第一附属医院普外科二病区, 安徽合肥 230022

基金项目:

国际科技合作计划（1303063016）

详细信息

作者简介:
宋均飞(1990-),男,安徽六安人,在读硕士研究生。主要研究方向:胃肠道肿瘤的诊治。

中图分类号: R349.39;R392.11;R735.35
计量
- 文章访问数: 235
- HTML全文浏览量: 46
- PDF下载量: 29
- 被引次数: 0
出版历程
- 收稿日期: 2015-11-08
- 修回日期: 2016-02-25

The expression and clinical signification of EGFR and HER2 in the serum and tumor tissue of colorectal cancer

SONG Jun-fei,
LIU Yi^,

Department of General Surgery Ward Two, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China

摘要

摘要: 目的检测表皮生长因子受体（epidermal growth factor receptor，EGFR）和人类表皮生长因子受体-2 （human epidermal growth factor receptor-2，HER2）在大肠癌（colorectal cancer，CRC）组织和外周血中的表达，探讨EGFR和HER2在CRC发生、发展中的作用，为CRC的诊断、预后判断提供方便、经济的检测方法。方法应用免疫组织化学法（immunohistochemical，IHC）测定76例CRC原发灶及癌旁正常组织（adjacent non-tumorous tissues，NT）及40例结直肠腺瘤组织中EGFR和HER2水平，应用酶联免疫吸附法（enzyme-linked immunosorbent assays，ELISA）检测40例健康志愿者和相应CRC患者血清EGFR和HER2。结果 NT和结直肠腺瘤组中EGFR和HER2含量均明显低于CRC原发灶（均有P<0.05），血清EGFR（t=14.845，P<0.001）和HER2（t=15.410，P<0.001）高于对照组；组织EGFR、HER2与淋巴结转移（lymph node metastasis，LNM）及Dukes分期有相关性（均有P<0.05），而和性别、年龄等无关（均有P>0.05）。结论 EGFR和HER2在CRC原发病灶组织和外周血中均呈高表达，且随着肿瘤浸润程度，转移的发展而增加，其异常表达在肿瘤的产生，发展中可能起着某种作用；血液中EGFR、HER2有作为新的肿瘤标志物可能。
- 结直肠肿瘤 /
- 受体,表皮生长因子 /
- 流行病学方法
Abstract: Objective To observe the expression level of epidermal growth factor receptor(EGFR)and human epidermal growth factor receptor-2 (HER2) in colorectal cancer (CRC) and discuss the role of EGFR and HER2 in CRC occurrence and development, so as to offer a possible new biomarker for diagnosis and prognosis of CRC. Methods Immunohistochemical (IHC) was used to detect the expression of tissue EGFR and HER2 in 76 cases of CRC primary lesion and normal tissue adjacent to carcinoma, 40 cases of colorectal adenomas. Preoperative serum samples were extracted from 76 cases of CRC and 40 healthy volunteers. Serum levels of EGFR and HER2 were determined by the enzyme-linked immunosorbent assays (ELISA). Results There was significant difference between the overexpression of EGFR and HER2 in CRC and the low expression in normal mucosa and adenoma(all P<0.05). Serum EGFR(t=14.845, P<0.001) and HER2 (t=15.410, P<0.001) were significantly higher in patients with CRC than those in normal control group. The level of EGFR and HER2 expression in tissue was correlated with lymph node metastasis and Dukes stage(all P<0.05), while without relation with sex, age,etc(all P>0.05). Conclusions The overexpression of EGFR and HER2 in CRC tissue and serum suggests that the expression of EGFR and HER2, and with the development of transfer the degree of tumor infiltration increased, which may play an important role in the occurrence and progress of CRC. Serum EGFR and HER2 can be used as new tumor markers.
- Colorectal neoplasms /
- Receptor, epidermal growth factor /
- Epidemiologic methods

HTML全文

参考文献(22)

Tsigris C, Karayiannakis AJ, Zbar A, et al. Clinical significance of serum and urinary c-HER2 levels in colorectal cancer [J]. Cancer Lett, 2002,184(2):215-222.

吴凡,叶韵斌,陆俐丽,等. 乳腺癌患者血清HER2的检测及其临床意义 [J]. 中国肿瘤生物治疗杂志, 2009,16(4):405-409.

Streckfus C, Bigler L, Dellinger T, et al. The presence of soluble c-HER2 in saliva and serum among women with breast carcinoma: a preliminary study [J]. Clin Cancer Res, 2000,6(6):2363-2370.

Kang SH, Cho J, Ha JS, et al. Evaluation of serum HER-2/neu extracelluar domain in breast cancer patients:correlation with tissue HER-2/neu status and clinicopathological factors [J]. J Korean Surg Soc, 2010,78(5):271-276.

Pathmanathan N, Bilous AM. HER2 testing in breast cancer: an overview of current techniques and recent developments [J]. Pathology, 2012,44(7):587-595.

Abdel-Aziz MM, Lotfy M, El-Kady IM, et al. Mutant p53 protein in the serum of patients with colorectal cancer: Correlation with the level of carcinoembryonic antigen and serum epidermal growth factor receptor [J]. Cancer Detect Prev, 2009,32(4):329-335.

焦裕荣,邵正萍,丁克峰. 结直肠癌转移的防治进展 [J]. 实用肿瘤杂志, 2014,29(6): 510-516.

王宁,孙婷婷,郑荣寿,等. 中国2009年结直肠癌发病和死亡资料分析 [J]. 中国肿瘤, 2013,22(7):515-520.

杨辉,朱瑞凯,冯向先,等. 1381例结直肠癌患者住院费用分析 [J]. 中华疾病控制杂志, 2014,18(7):679-682.

刘茉,王亚东,王贵齐,等. 基于慢病管理的结直肠癌筛查模式初探 [J]. 中华疾病控制杂志, 2015,19(5):525-527.

Leporrier J, Maurel J, Chiche L, et al. A population‐based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer [J]. Br J Surg, 2006,93(4):465-474.

Xue Y, Yu F, Yan D, et al. Zinc-α-2-glycoprotein: a candidate biomarker for colon cancer diagnosis in Chinese population [J]. Int J Mol Sci, 2014,16(1):691-703.

曾瑄,王鹏,武莎斐,等. 结直肠癌EGFR和HER2蛋白表达及其基因拷贝数分析 [J]. 中华病理学杂志, 2007,36(7):447-452.

Lu Y, Jingyan G, Baorong S, et al. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer [J]. Cancer Biomark, 2012,11(5):219-226.

Sasaki H, Yukiue H, Mizuno K, et al. Elevated serum epidermal growth factor receptor level is correlated with lymph node metastasis in lung cancer [J]. Int J Clin Oncol, 2003,8(2):79-82.

Garcia I, Vizoso F, Martin A, et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer [J]. Ann Surg Onco, 2003,10(3):234-241.

Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J]. Lancet, 2010,376(9742):687-697.

Mukai H. Targeted therapy in breast cancer: current status and future directions [J]. Jpn J Clin Oncol, 2010,40(8):711-716.

Half E, Broaddus R, Danenberg KD, et al. HER‐2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors [J]. Int J Cancer, 2004,108(4):540-548.

Jørgensen JT. Targeted HER2 treatment in advanced gastric cancer [J]. Oncology, 2010,78(1):26-33.

Galizia G, Lieto E, Ferraraccio F, et al. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery [J]. Ann Surg Oncol, 2006,13(6):823-835.

Oyama K, Fushida S, Tsukada T, et al. Evaluation of serum HER2-ECD levels in patients with gastric cancer [J]. J Gastroenterol, 2015,50(1):41-45.

施引文献

资源附件(0)

访问统计